NCT03132467 2024-06-05
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
Clinical Trials
3 trialsNCT04088032 2020-07-16
Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
Stony Brook University
Phase EARLY_PHASE1 Withdrawn
NCT02802098 2020-06-19
Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase EARLY_PHASE1 Completed